Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells 15,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $61.92, for a total transaction of $928,800.00. Following the transaction, the chief executive officer now owns 477,847 shares of the company’s stock, valued at $29,588,286.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Grant Pickering also recently made the following trade(s):

• On Monday, March 25th, Grant Pickering sold 15,000 shares of Vaxcyte stock. The shares were sold at an average price of $66.93, for a total transaction of $1,003,950.00.
• On Friday, March 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $73.70, for a total transaction of $192,799.20.
• On Thursday, February 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The stock was sold at an average price of $73.91, for a total transaction of $193,348.56.
• On Monday, January 29th, Grant Pickering sold 30,000 shares of Vaxcyte stock. The stock was sold at an average price of $66.03, for a total transaction of $1,980,900.00.

Vaxcyte Stock Down 0.4 %

Shares of PCVX stock opened at $60.06 on Friday. Vaxcyte, Inc. has a 52 week low of $41.57 and a 52 week high of $82.04. The firm’s 50-day simple moving average is $68.25 and its two-hundred day simple moving average is $61.27.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same period last year, the company earned ($0.73) EPS. Research analysts expect that Vaxcyte, Inc. will post -4.18 earnings per share for the current year.

Institutional Trading of Vaxcyte

Several hedge funds and other institutional investors have recently modified their holdings of the business. Raymond James & Associates raised its position in shares of Vaxcyte by 28.7% in the first quarter. Raymond James & Associates now owns 66,332 shares of the company’s stock valued at $4,531,000 after purchasing an additional 14,779 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of Vaxcyte by 109.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 47,388 shares of the company’s stock valued at $3,237,000 after purchasing an additional 24,785 shares during the period. Banque Cantonale Vaudoise raised its position in shares of Vaxcyte by 96.7% in the first quarter. Banque Cantonale Vaudoise now owns 1,184 shares of the company’s stock valued at $81,000 after purchasing an additional 582 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Vaxcyte by 25.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 6,986 shares of the company’s stock valued at $439,000 after purchasing an additional 1,411 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Vaxcyte by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 8,452,371 shares of the company’s stock valued at $530,809,000 after purchasing an additional 168,125 shares during the period. Institutional investors own 96.78% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Bank of America boosted their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 2nd. Finally, Needham & Company LLC restated a “buy” rating and set a $95.00 price target on shares of Vaxcyte in a report on Wednesday, April 10th. Four analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vaxcyte has a consensus rating of “Buy” and a consensus price target of $78.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.